
COMMISSION DELEGATED REGULATION (EU) 2020/1182 of 19 May 2020 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance) 

THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, and in particular Article 37(5) thereof,
Whereas:

(1) Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.

(2) Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of the Agency (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete the harmonised classification and labelling of certain substances. Those RAC opinions are: 


— Opinion of 8 June 2018 concerning nitric acid ... %[C ≤ 70 %];
— Opinion of 9 March 2018 concerning silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1);
— Opinion of 8 June 2018 concerning trimethoxyvinylsilane; trimethoxy(vinyl)silane;
— Opinion of 8 June 2018 concerning tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane;
— Opinion of 8 June 2018 concerning dimethyl disulphide;
— Opinion of 8 June 2018 concerning granulated copper;
— Opinion of 30 November 2018 concerning bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O')copper; bis(N-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO];
— Opinion of 14 September 2018 concerning dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2];
— Opinion of 30 November 2018 concerning dibenzo[def,p]chrysene; dibenzo[a,l]pyrene;
— Opinion of 9 March 2018 concerning ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol;
— Opinion of 8 June 2018 concerning bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme;
— Opinion of 8 June 2018 concerning paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol;
— Opinion of 8 June 2018 concerning 2,2-bis(bromomethyl)propane-1,3-diol;
— Opinion of 14 September 2018 concerning geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol;
— Opinion of 28 January 2019 concerning 2-(4-tert-butylbenzyl)propionaldehyde;
— Opinion of 9 March 2018 concerning MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate;
— Opinion of 9 March 2018 concerning diisooctyl phthalate;
— Opinion of 14 September 2018 concerning 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl) amino}furan-2(5H)-one; flupyradifurone;
— Opinion of 30 November 2018 concerning thiencarbazone-methyl (ISO); methyl 4- [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5-methylthiophene-3-carboxylate;
— Opinion of 9 March 2018 concerning L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid;
— Opinion of 9 March 2018 concerning 2-methoxyethyl acrylate;
— Opinion of 8 June 2018 concerning glyoxylic acid …%;
— Opinion of 14 September 2018 concerning sodium N-(hydroxymethyl)glycinate; [formaldehyde released from sodium N-(hydroxymethyl)glycinate];
— Opinion of 30 November 2018 concerning potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO];
— Opinion of 14 September 2018 concerning mecetronium etilsulfate; N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate [MES];
— Opinion of 9 March 2018 concerning (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole;
— Opinion of 30 November 2018 concerning oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone;
— Opinion of 14 September 2018 concerning pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O) pyridine-2(1H)-thionato-.kappa.S]zinc;
— Opinion of 30 November 2018 concerning 3-chloro-4-(chloromethyl)-1-[3-trifluoromethyl)phenyl]pyrrolidin-2-one; flurochloridone (ISO);
— Opinion of 30 November 2018 concerning 4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT];
— Opinion of 8 June 2018 concerning 2-methyl-1,2-benzothiazol-3(2H)-one; [MBIT];
— Opinion of 30 November 2018 concerning 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad;
— Opinion of 8 June 2018 concerning N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA];
— Opinion of 15 October 2018 concerning 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2’-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen;
— Opinion of 30 November 2018 concerning iprovalicarb(ISO); isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate;
— Opinion of 30 November 2018 concerning silthiofam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide;
— Opinion of 9 March 2018 concerning Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide];
— Opinion of 8 June 2018 concerning nitric acid …%[C> 70 %];
— Opinion of 9 March 2018 concerning octamethylcyclotetrasiloxane; [D4];
— Opinion of 30 November 2018 concerning pirimiphos-methyl (ISO); O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate;
— Opinion of 30 November 2018 concerning phosphine;
— Opinion of 14 September 2018 concerning dichlorodioctylstannane;
— Opinion of 30 November 2018 concerning 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE];
— Opinion of 30 November 2018 concerning lead;
— Opinion of 14 September 2018 concerning 2-butoxyethanol; ethylene glycol monobutyl ether;
— Opinion of 30 November 2018 concerning m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether;
— Opinion of 14 September 2018 concerning tribenuron-methyl (ISO); methyl 2- [N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate;
— Opinion of 8 June 2018 concerning azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate;
— Opinion of 9 March 2018 concerning ethofumesate (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate;
— Opinion of 30 November 2018 concerning 2,4-dinitrophenol;
— Opinion of 14 September 2018 concerning mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione;
— Opinion of 30 November 2018 concerning octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT];
— Opinion of 14 September 2018 concerning hymexazol (ISO); 3-hydroxy-5-methylisoxazole;
— Opinion of 30 November 2018 concerning hexythiazox (ISO); trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide;
— Opinion of 9 March 2018 concerning pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethylene amino)-1,2,4-triazin-3(2H)-one;
— Opinion of 9 March 2018 concerning imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate;
— Opinion of 14 September 2018 concerning butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime;
— Opinion of 8 June 2018 concerning bis(α,α-dimethylbenzyl) peroxide;
— Opinion of 9 March 2018 concerning branched hexatriacontane;
— Opinion of 30 November 2018 concerning hexyl 2-(1-(diethylaminohydroxyphenyl) methanoyl)benzoate; hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.

(3) With regard to the substance lead (CAS number 7439-92-1 and index numbers 082-013-00-1 (lead powder; [particle diameter < 1 mm];) and 082-014-00-7 (lead massive; [particle diameter ≥ 1 mm];)), RAC proposed in its opinion of 30 November 2018 to apply the same environmental classification to the massive and the powder form. However, in view of the lower dissolution rate of the massive form, the malleable structure of lead, the specific intentional production of the powder and the different environmental classification between massive and powder forms for existing entries in Annex VI for other metals, further assessment needs to be done by RAC on whether to apply the same environmental classification to the massive as to the powder form of lead. In addition, new scientific data has been made available suggesting that the environmental classification for the massive form as recommended in the RAC opinion might not be appropriate Therefore, the environmental classification for the massive form will not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has had the opportunity to deliver a revised opinion.

(4) With regard to the substance 2-butoxyethanol; ethylene glycol monobutyl ether; (CAS number 111-76-2), new scientific data has been made available for the hazard class ‘acute toxicity (inhalation)’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be modified in Annex VI to Regulation (EC) No 1272/2008 until RAC has had the opportunity to deliver a revised opinion based on the new information, while all other hazard classes covered by the RAC opinion should be included.

(5) Regulation (EC) No 1272/2008 should therefore be amended accordingly.

(6) Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Such requirements may include those set out in point (f) of Article 22(1) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council or those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council.

(7) Suppliers should, however, have the possibility to apply the new classification, labelling and packaging provisions on a voluntary basis before the date of application of this Regulation. This is consistent with the approach taken under Article 61(2) of Regulation (EC) No 1272/2008,
HAS ADOPTED THIS REGULATION:

Amendments to Regulation (EC) No 1272/2008
Article 1 
Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.
Entry into force and application
Article 2 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 1 March 2022.
By way of derogation from the second paragraph of this Article, substances and mixtures may, before 1 March 2022 be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 19 May 2020.
For the Commission
The President
Ursula VON DER LEYEN
ANNEX

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

((1)) the following entries are inserted:

Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
‘007-030-00-3 nitric acid …% [C ≤ 70 %] 231-714-2 7697-37-2. Ox. Liq. 3Acute Tox. 3Skin Corr. 1A H272H331H314 GHS03GHS06GHS05Dgr H272H331H314 EUH071 Ox. Liq. 3; H272: C ≥ 65 %inhalation: ATE = 2,65 mg/L (vapours)Skin Corr. 1A; H314: C ≥ 20 %Skin Corr. 1B; H314: 5 % ≤ C < 20 % B’
‘014-048-00-5 silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) 206-991-8 409-21-2308076-74-6 Carc. 1B H350i GHS08Dgr H350i’   
‘014-049-00-0 trimethoxyvinylsilane; trimethoxy(vinyl)silane 220-449-8 2768-02-7 Skin Sens. 1B H317 GHS07Wng H317’   
‘014-050-00-6 tris(2-methoxyethoxy)vinylsilane;6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane 213-934-0 1067-53-4 Repr. 1B H360FD GHS08Dgr H360FD’   
‘016-098-00-3 dimethyl disulphide 210-871-0 624-92-0 Flam. Liq. 2Acute Tox. 3Acute Tox. 3STOT SE 3STOT SE 1Eye Irrit. 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H225H331H301H336H370 (upper respiratory tract, inhalation)H319H317H400H410 GHS02GHS06GHS08GHS09Dgr H225H331H301H336H370 (upper respiratory tract, inhalation)H319H317H410  inhalation: ATE = 5 mg/L (vapours)oral: ATE = 190 mg/kg bwM = 1M = 10’ 
‘029-024-00-X granulated copper;[particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm] 231-159-6 7440-50-8 Aquatic Chronic 2 H411 GHS09 H411’   
‘029-025-00-5 bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper;bis(N-cyclohexyl-diazenium-dioxy)-copper;[Cu-HDO] 239-703-4 312600-89-815627-09-5 Flam. Sol. 1Acute Tox. 4STOT RE 2Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H228H302H373 (liver)H318H400H410 GHS02GHS07GHS08GHS05GHS09Dgr H228H302H373(liver)H318H410  oral: ATE = 360 mg/kg bwM = 1M = 1’ 
‘050-031-00-9 dioctyltin dilaurate; [1]stannane, dioctyl-, bis(coco acyloxy) derivs. [2] 222-883-3 [1] 293-901-5 [2] 3648-18-8 [1] 91648-39-4 [2] Repr. 1BSTOT RE 1 H360DH372 (immune system) GHS08Dgr H360DH372 (immune system)’   
‘601-092-00-0 dibenzo[def,p]chrysene;dibenzo[a,l]pyrene 205-886-4 191-30-0 Carc. 1BMuta. 2 H350H341 GHS08Dgr H350H341  Carc. 1B; H350: C ≥ 0,001 %’ 
‘603-237-00-3 ipconazole (ISO);(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol - 125225-28-7115850-69-6115937-89-8 Repr. 1BAcute Tox. 4STOT RE 2Aquatic Chronic 1 H360DH302H373 (eyes, skin, liver)H410 GHS08GHS07GHS09Dgr H360DH302H373 (eyes, skin, liver)H410  oral: ATE = 500 mg/kg bwM = 100’ 
‘603-238-00-9 bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme 205-594-7 143-24-8 Repr. 1B H360FD GHS08Dgr H360FD’   
‘603-239-00-4 paclobutrazol (ISO);(2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol - 76738-62-0 Repr. 2Acute Tox. 4Acute Tox. 4Eye Irrit. 2Aquatic Acute 1Aquatic Chronic 1 H361dH332H302H319H400H410 GHS08GHS07GHS09Wng H361dH332H302H319H410  inhalation: ATE = 3,13 mg/L (dusts or mists)oral: ATE = 490 mg/kg bwM = 10M = 10’ 
‘603-240-00-X 2,2-bis(bromomethyl)propane-1,3-diol 221-967-7 3296-90-0 Carc. 1BMuta. 1B H350H340 GHS08Dgr H350H340’   
‘603-241-00-5 geraniol;(2E)-3,7-dimethylocta-2,6-dien-1-ol 203-377-1 106-24-1 Skin Sens. 1 H317 GHS07Wng H317’   
‘605-041-00-3 2-(4-tert-butylbenzyl)propionaldehyde 201-289-8 80-54-6 Repr. 1B H360Fd GHS08Dgr H360Fd’   
‘607-738-00-8 MCPA-thioethyl (ISO);S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate 246-831-4 25319-90-8 Acute Tox. 4STOT RE. 2Aquatic Acute 1 Aquatic Chronic 1 H302H373 (liver)H400H410 GHS07GHS08GHS09Wng H302H373 (liver)H410  oral: ATE = 450 mg/kg bwM = 10M = 10’ 
‘607-740-00-9 diisooctyl phthalate 248-523-5 27554-26-3 Repr. 1B H360FD GHS08Dgr H360FD’   
‘607-741-00-4 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone - 951659-40-8 Acute Tox. 4STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H302H373 (muscle)H400H410 GHS07GHS08GHS09Wng H302H373 (muscle)H410  oral: ATE = 500 mg/kg bwM = 10M = 10’ 
‘607-742-00-X thiencarbazone-methyl (ISO);methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate - 317815-83-1 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1000M = 1000’ 
‘607-743-00-5 L-(+)-lactic acid;(2S)-2-hydroxypropanoic acid 201-196-2 79-33-4 Skin Corr. 1CEye Dam. 1 H314H318 GHS05Dgr H314 EUH071’  
‘607-744-00-0 2-methoxyethyl acrylate 221-499-3 3121-61-7 Flam. Liq. 3Muta. 2Repr. 1BAcute Tox. 3Acute Tox. 4Skin Corr. 1CEye Dam. 1Skin Sens. 1 H226H341H360FDH331H302H314H318H317 GHS02GHS05GHS06GHS08Dgr H226H341H360FDH331H302H314H317 EUH071 inhalation: ATE = 2,7 mg/L (vapours)oral: ATE = 404 mg/kg bw’ 
‘607-745-00-6 glyoxylic acid …% 206-058-5 298-12-4 Eye Dam. 1Skin Sens. 1B H318H317 GHS05GHS07Dgr H318H317   B’
‘607-746-00-1 sodium N-(hydroxymethyl)glycinate;[formaldehyde released from sodium N-(hydroxymethyl)glycinate] 274-357-8 70161-44-3 Carc. 1BMuta. 2Acute Tox. 4Acute Tox. 4STOT SE 3Skin Irrit. 2Eye Irrit. 2Skin Sens. 1 H350H341H332H302H335H315H319H317 GHS08GHS07Dgr H350H341H332H302H335H315H319H317  inhalation: ATE = 3 mg/L (dusts or mists)oral: ATE = 1100 mg/kg bw 89’
‘611-181-00-6 potassium (oxido-NNO-azoxy)cyclohexane;cyclohexylhydroxydiazene 1-oxide, potassium salt;[K-HDO] - 66603-10-9 Flam. Sol. 1Acute Tox. 3STOT RE 2Skin Irrit. 2Eye Dam. 1Aquatic Chronic 2 H228H301H373 (liver)H315H318H411 GHS02GHS06GHS08GHS05GHS09Dgr H228H301H373 (liver)H315H318H411  oral: ATE = 136 mg/kg bw’ 
‘612-294-00-3 mecetronium etilsulfate;N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate;mecetronium ethyl sulphate;[MES] 221-106-5 3006-10-8 Skin Corr. 1Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H314H318H400H410 GHS05GHS09Dgr H314H410 EUH071 M = 100M = 1000’ 
‘613-331-00-6 (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;mefentrifluconazole - 1417782-03-6 Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H317H400H410 GHS07GHS09Wng H317H410  M = 1M = 1’ 
‘613-332-00-1 oxathiapiprolin (ISO);1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone - 1003318-67-9 Aquatic Chronic 1 H410 GHS09Wng H410  M = 1’ 
‘613-333-00-7 pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc 236-671-3 13463-41-7 Repr. 1BAcute Tox. 2Acute Tox. 3STOT RE 1Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 H360DH330H301H372H318H400H410 GHS08GHS06GHS05GHS09Dgr H360DH330H301H372H318H410  inhalation: ATE = 0,14 mg/L (dusts or mists)oral: ATE = 221 mg/kg bwM = 1000M = 10’ 
‘613-334-00-2 flurochloridone (ISO);3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one 262-661-3 61213-25-0 Repr. 1BAcute Tox. 4Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H360FDH302H317H400H410 GHS08GHS07GHS09Dgr H360FDH302H317H410  oral: ATE = 500 mg/kg bwM = 100M = 100’ 
‘613-335-00-8 4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT] 264-843-8 64359-81-5 Acute Tox. 2Acute Tox. 4Skin Corr. 1Eye Dam. 1Skin Sens. 1AAquatic Acute 1Aquatic Chronic 1 H330H302H314H318H317H400H410 GHS06GHS05GHS09Dgr H330H302H314H317H410 EUH071 inhalation: ATE = 0,16 mg/L (dusts or mists)oral: ATE = 567 mg/kg bwSkin Irrit. 2; H315: 0,025 % ≤ C < 5 %Eye Irrit. 2; H319: 0,025 % ≤ C < 3 %Skin Sens. 1A; H317: C ≥ 0,0015 %M = 100M = 100’ 
‘613-336-00-3 2-methyl-1,2-benzothiazol-3(2H)-one;[MBIT] - 2527-66-4 Acute Tox. 4Acute Tox. 3Skin Corr. 1CEye Dam. 1Skin Sens. 1AAquatic Acute 1Aquatic Chronic 2 H312H301H314H318H317H400H411 GHS06GHS05GHS09Dgr H312H301H314H317H410 EUH071 dermal: ATE = 1100 mg/kg bworal: ATE = 175 mg/kg bwSkin Sens. 1A; H317: C ≥ 0,0015 %M = 1’ 
‘616-228-00-4 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide;fluxapyroxad - 907204-31-3 Lact.Aquatic Acute 1Aquatic Chronic 1 H362H400H410 GHS09Wng H362H410  M = 1M = 1’ 
‘616-230-00-5 N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] 213-103-2 924-42-5 Carc. 1BMuta. 1BSTOT RE 1 H350H340H372 (peripheral nervous system) GHS08Dgr H350H340H372 (peripheral nervous system)’   
‘616-231-00-0 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide;penflufen - 494793-67-8 Carc. 2Aquatic Acute 1Aquatic Chronic 1 H351H400H410 GHS08GHS09Wng H351H410  M = 1M = 1’ 
‘616-232-00-6 iprovalicarb (ISO);isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate - 140923-17-7 Carc. 2 H351 GHS08Wng H351’   
‘616-233-00-1 silthiofam (ISO);N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide - 175217-20-6 STOT RE 2Aquatic Chronic 2 H373H411 GHS08GHS09Wng H373H411’   
‘650-057-00-6 Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] 283-644-7 84696-25-3 Aquatic Chronic 3 H412  H412’   
((2)) the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:

Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
‘007-004-00-1 nitric acid …% [C > 70 %] 231-714-2 7697-37-2 Ox. Liq. 2Acute Tox. 1Skin Corr. 1A H272H330H314 GHS03GHS06GHS05Dgr H272H330H314 EUH071 Ox. Liq. 2; H272: C ≥ 99 %Ox. Liq. 3; H272: 70 % ≤ C < 99 % B’
‘014-018-00-1 octamethylcyclotetrasiloxane;[D4] 209-136-7 556-67-2 Repr. 2Aquatic Chronic 1 H361f ***H410 GHS08GHS09Wng H361f ***H410  M = 10’ 
‘015-134-00-5 pirimiphos-methyl (ISO);O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate 249-528-5 29232-93-7 Acute Tox. 4STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H302H372 (nervous system)H400H410 GHS07GHS08GHS09Dgr H302H372 (nervous system)H410  oral: ATE = 1414 mg/kg bwM = 1000M = 1000’ 
‘015-181-00-1 phosphine 232-260-8 7803-51-2 Flam. Gas 1Press. GasAcute Tox. 1Skin Corr. 1BAquatic Acute 1 H220H330H314H400 GHS02GHS04GHS06GHS05GHS09Dgr H220H330H314H400  inhalation:ATE = 10 ppmV (gases) U’
‘050-021-00-4 dichlorodioctylstannane 222-583-2 3542-36-7 Repr. 1BAcute Tox. 2STOT RE 1Aquatic Chronic 3 H360DH330H372 **H412 GHS08GHS06Dgr H360DH330H372 **H412  Repr. 1B; H360 D: C ≥ 0,03 %inhalation: ATE = 0,098 mg/L (dusts or mists)’ 
‘050-027-00-7 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE] 239-622-4 15571-58-1 Repr. 1BSTOT RE 1Aquatic Acute 1Aquatic Chronic 1 H360DH372 (immune system)H400H410 GHS08GHS09Dgr H360DH372 (immune system)H410’   
‘082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1ALact.Aquatic Acute 1Aquatic Chronic 1 H360FDH362H400H410 GHS08GHS09Dgr H360FD H362H410  Repr. 1A; H360D: C ≥ 0,03 %M = 1M = 10’ 
‘603-014-00-0 2-butoxyethanol;ethylene glycol monobutyl ether 203-905-0 111-76-2 Acute Tox. 4*Acute Tox. 4Skin Irrit. 2Eye Irrit. 2 H332H302H315H319 GHS07Wng H332H302H315H319  oral: ATE = 1200 mg/kg bw’ 
‘603-065-00-9 m-bis(2,3-epoxypropoxy)benzene;resorcinol diglycidyl ether 202-987-5 101-90-6 Carc. 1BMuta. 2Acute Tox. 3Acute Tox. 4Skin Irrit. 2Eye Irrit. 2Skin Sens. 1Aquatic Chronic 3 H350H341H311H302H315H319H317H412 GHS08GHS06Dgr H350H341H311H302H315H319H317H412  dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’ 
‘607-177-00-9 tribenuron-methyl (ISO);methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate 401-190-1 101200-48-0 STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H373H317H400H410 GHS08GHS07GHS09Wng H373H317H410  M = 100M = 100’ 
‘607-256-00-8 azoxystrobin (ISO);methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate - 131860-33-8 Acute Tox. 3Aquatic Acute 1Aquatic Chronic 1 H331H400H410 GHS06GHS09Dgr H331H410  inhalation:ATE = 0,7 mg/L (dusts or mists)M = 10M = 10’ 
‘607-314-00-2 ethofumesate (ISO);(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate 247-525-3 26225-79-6 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1M = 1’ 
‘609-041-00-4 2,4-dinitrophenol 200-087-7 51-28-5 Acute Tox. 3 *Acute Tox. 3Acute Tox. 2STOT RE 1Aquatic Acute 1 H331H311H300H372H400 GHS06GHS08GHS09Dgr H331H311H300H372H400  dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’ 
‘609-064-00-X mesotrione (ISO);2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione - 104206-82-8 Repr. 2STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H361dH373 (eyes, nervous system)H400H410 GHS08GHS09Wng H361dH373 (eyes, nervous system)H410  M = 10M = 10’ 
‘613-112-00-5 octhilinone (ISO);2-octyl-2H-isothiazol-3-one; [OIT] 247-761-7 26530-20-1 Acute Tox. 2Acute Tox. 3Acute Tox. 3Skin Corr. 1Eye Dam. 1Skin Sens. 1AAquatic Acute 1 Aquatic Chronic 1 H330H311H301H314H318H317H400H410 GHS06GHS05GHS09Dgr H330H311H301H314H317H410 EUH071 inhalation: ATE = 0,27 mg/L (dusts or mists)dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bwSkin Sens. 1A; H317: C ≥ 0,0015 %M = 100M = 100’ 
‘613-115-00-1 hymexazol (ISO);3-hydroxy-5-methylisoxazole 233-000-6 10004-44-1 Repr. 2Acute Tox. 4Eye Dam. 1Skin Sens. 1Aquatic Chronic 2 H361dH302H318H317H411 GHS08GHS07GHS05GHS09Dgr H361dH302H318H317H411  oral: ATE = 1600 mg/kg bw’ 
‘613-125-00-6 hexythiazox (ISO);trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide - 78587-05-0 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1M = 1’ 
‘613-202-00-4 pymetrozine (ISO);(E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one - 123312-89-0 Carc. 2Repr. 2Aquatic Chronic 1 H351H361fdH410 GHS08GHS09Wng H351H361fdH410  M = 1’ 
‘613-259-00-5 imiprothrin (ISO);reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate 428-790-6 72963-72-5 Carc. 2Acute Tox. 4Acute Tox. 4STOT SE 2Aquatic Acute 1Aquatic Chronic 1 H351H332H302H371 (nervous system; oral, inhalation)H400H410 GHS08GHS07GHS09Wng H351H332H302H371 (nervous system; oral, inhalation)H410  inhalation: ATE = 1,4 mg/L (dusts or mists)oral: ATE = 550 mg/kg bwM = 10M = 10’ 
‘616-014-00-0 butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime 202-496-6 96-29-7 Carc. 1BAcute Tox. 4Acute Tox. 3STOT SE 3STOT SE 1STOT RE 2Skin Irrit. 2Eye Dam. 1Skin Sens. 1 H350H312H301H336H370 (upper respiratory tract)H373 (blood system)H315H318H317 GHS08GHS06GHS05Dgr H350H312H301H336H370 (upper respiratory tract)H373 (blood system)H315H318H317  dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’ 
‘617-006-00-X bis(α,α-dimethylbenzyl) peroxide 201-279-3 80-43-3 Org. Perox. FRepr. 1BSkin Irrit. 2Eye Irrit. 2Aquatic Chronic 2 H242H360DH315H319H411 GHS02GHS08GHS07GHS09Dgr H242H360DH315H319H411’   
((3)) the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.
